Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 2
1973 1
1976 2
1978 1
1979 6
1981 3
1983 1
1984 4
1985 4
1986 4
1987 3
1988 8
1989 6
1990 7
1991 5
1992 10
1993 7
1994 9
1995 7
1996 6
1997 11
1998 8
1999 5
2000 3
2001 6
2002 5
2003 4
2004 6
2005 6
2006 6
2007 7
2008 8
2009 20
2010 9
2011 13
2012 13
2013 14
2014 15
2015 11
2016 15
2017 15
2018 12
2019 12
2020 11
2021 15
2022 20
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

352 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Malignant hyperthermia of anesthesia"
Page 1
Adverse drug reactions.
Patton K, Borshoff DC. Patton K, et al. Anaesthesia. 2018 Jan;73 Suppl 1:76-84. doi: 10.1111/anae.14143. Anaesthesia. 2018. PMID: 29313907 Free article. Review.
Of the wide spectrum of adverse drug reactions, the most concerning to the anaesthetist remain anaphylaxis and malignant hyperthermia. Although the incidence of anaphylaxis under anaesthesia is difficult to ascertain, it occurs commonly enough that most anaes …
Of the wide spectrum of adverse drug reactions, the most concerning to the anaesthetist remain anaphylaxis and malignant hyperther …
Malignant hyperthermia 2020: Guideline from the Association of Anaesthetists.
Hopkins PM, Girard T, Dalay S, Jenkins B, Thacker A, Patteril M, McGrady E. Hopkins PM, et al. Anaesthesia. 2021 May;76(5):655-664. doi: 10.1111/anae.15317. Epub 2021 Jan 5. Anaesthesia. 2021. PMID: 33399225 Free article.
Malignant hyperthermia is defined in the International Classification of Diseases as a progressive life-threatening hyperthermic reaction occurring during general anaesthesia. Malignant hyperthermia has an underlying genetic basis, and genetical …
Malignant hyperthermia is defined in the International Classification of Diseases as a progressive life-threatening hypertherm …
European Resuscitation Council Guidelines 2021: Cardiac arrest in special circumstances.
Lott C, Truhlář A, Alfonzo A, Barelli A, González-Salvado V, Hinkelbein J, Nolan JP, Paal P, Perkins GD, Thies KC, Yeung J, Zideman DA, Soar J; ERC Special Circumstances Writing Group Collaborators. Lott C, et al. Resuscitation. 2021 Apr;161:152-219. doi: 10.1016/j.resuscitation.2021.02.011. Epub 2021 Mar 24. Resuscitation. 2021. PMID: 33773826
This section provides guidelines on the modifications required to basic and advanced life support for the prevention and treatment of cardiac arrest in special circumstances; specifically special causes (hypoxia, trauma, anaphylaxis, sepsis, hypo/hyperkalaemia and other electroly …
This section provides guidelines on the modifications required to basic and advanced life support for the prevention and treatment of cardia …
The anaesthetist, opioid analgesic drugs, and serotonin toxicity: a mechanistic and clinical review.
Baldo BA, Rose MA. Baldo BA, et al. Br J Anaesth. 2020 Jan;124(1):44-62. doi: 10.1016/j.bja.2019.08.010. Epub 2019 Oct 22. Br J Anaesth. 2020. PMID: 31653394 Free article. Review.
The intraoperative recognition of serotonin toxicity is challenging as it can mimic other serious syndromes, such as malignant hyperthermia, sepsis, thyroid storm, and neuroleptic malignant syndrome. ...
The intraoperative recognition of serotonin toxicity is challenging as it can mimic other serious syndromes, such as malignant hyp …
Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group.
Rüffert H, Bastian B, Bendixen D, Girard T, Heiderich S, Hellblom A, Hopkins PM, Johannsen S, Snoeck MM, Urwyler A, Glahn KPE; European Malignant Hyperthermia Group. Rüffert H, et al. Br J Anaesth. 2021 Jan;126(1):120-130. doi: 10.1016/j.bja.2020.09.029. Epub 2020 Oct 31. Br J Anaesth. 2021. PMID: 33131754 Free article.
The present guidelines are intended to bundle the available knowledge about perioperative management of malignant hyperthermia-susceptible patients and the preparation of anaesthesia workstations. ...The most crucial recommendation is that malignant …
The present guidelines are intended to bundle the available knowledge about perioperative management of malignant hyperthermia …
Malignant hyperthermia.
Rosenberg H, Davis M, James D, Pollock N, Stowell K. Rosenberg H, et al. Orphanet J Rare Dis. 2007 Apr 24;2:21. doi: 10.1186/1750-1172-2-21. Orphanet J Rare Dis. 2007. PMID: 17456235 Free PMC article. Review.
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to potent volatile anesthetic gases such as halothane, sevoflurane, desflurane and the depolarizing muscle relaxant succinylcholine, and rarely, i …
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to pot …
Epidemiological and clinical features of malignant hyperthermia: A scoping review.
Cong Z, Wan T, Wang J, Feng L, Cao C, Li Z, Wang X, Han Y, Zhou Y, Gao Y, Zhang J, Qu Y, Guo X. Cong Z, et al. Clin Genet. 2024 Mar;105(3):233-242. doi: 10.1111/cge.14475. Epub 2023 Dec 26. Clin Genet. 2024. PMID: 38148504 Review.
Malignant hyperthermia (MH) is a potentially fatal inherited pharmacogenetic disorder related to pathogenic variants in the RYR1, CACNA1S, or STAC3 genes. ...Identified risk factors included sex, age, disorders associated with MH, and others. The most frequent initi …
Malignant hyperthermia (MH) is a potentially fatal inherited pharmacogenetic disorder related to pathogenic variants in the RY …
Anesthetic consideration for neuromuscular diseases.
Katz JA, Murphy GS. Katz JA, et al. Curr Opin Anaesthesiol. 2017 Jun;30(3):435-440. doi: 10.1097/ACO.0000000000000466. Curr Opin Anaesthesiol. 2017. PMID: 28448298 Review.
The use of succinylcholine should be avoided in muscular dystrophies, motor neuron diseases, and intrinsic muscle disease due to a risk of malignant hyperthermia, hyperkalemia, rhabdomyolysis, and cardiac arrest. ...
The use of succinylcholine should be avoided in muscular dystrophies, motor neuron diseases, and intrinsic muscle disease due to a risk of …
Neuromuscular disease and anesthesia.
Romero A, Joshi GP. Romero A, et al. Muscle Nerve. 2013 Sep;48(3):451-60. doi: 10.1002/mus.23817. Epub 2013 Jul 27. Muscle Nerve. 2013. PMID: 23424048 Review.
Drugs that potentiate neuromuscular blocking drugs should also be avoided or their doses limited if possible. The risk of malignant hyperthermia in certain neuromuscular diseases mandates avoidance of triggering agents such as succinylcholine and inhaled anesthetics …
Drugs that potentiate neuromuscular blocking drugs should also be avoided or their doses limited if possible. The risk of malignant …
Anesthesiological approach to the floppy child.
Tesoro S, DE Robertis E, Marturano F, VAN DEN Hout HJ, DE Graaff JC. Tesoro S, et al. Minerva Anestesiol. 2021 Aug;87(8):940-949. doi: 10.23736/S0375-9393.20.15011-9. Epub 2021 Jan 12. Minerva Anestesiol. 2021. PMID: 33432795 Free article. Review.
Most patients are sensitive to the cardiac and depressive effects of anesthetics and all dystrophic myopathies are considered at risk of malignant hyperthermia. Depolarizing neuromuscular blockers are contraindicated. ...
Most patients are sensitive to the cardiac and depressive effects of anesthetics and all dystrophic myopathies are considered at risk of …
352 results